Investment Rating - Investment rating: Positive (maintained) [5] Core Insights - The report highlights the ongoing development and opportunities in the media and internet sectors, particularly focusing on AI applications and their integration into various platforms [7][8][12] - The gaming sector is expected to see significant growth with new product launches and high user engagement, particularly during the holiday season [6][9] - The film and television industry is poised for growth with new policies promoting content creation and distribution, alongside anticipated successful releases [9][51] Summary by Relevant Sections Gaming Sector - The upcoming limited test for the game "异环" is set to begin on February 4, with significant user engagement expected from major titles like "三角洲行动" and "超自然行动组" [6] - Major gaming companies are advised to be monitored for their exploration of AI integration, which could lead to a reevaluation of their market value [6] Internet Sector - The report emphasizes the importance of AI Agent technology and the competitive landscape for AI applications, suggesting that major companies like Tencent and Alibaba will continue to leverage their platform advantages [8] - The ongoing adjustments in organizational structures within leading internet companies are seen as strategically valuable for long-term growth [8] Film and Television Sector - The film "飞驰人生 3" is officially scheduled for release during the 2026 Spring Festival, with recommendations to monitor related production and distribution companies [9] - The television industry is expected to benefit from new government initiatives aimed at enhancing content supply, with a focus on long-form video platforms and production companies [9] Company Performance - Perfect World anticipates a net profit of between 720 million and 760 million, while Century Huatong expects a significant revenue increase of approximately 68% year-on-year [11][39] - Jiubang Technology forecasts a net profit increase of 79% to 97% for 2025, reflecting strong operational performance [41] Market Overview - The media sector showed a slight increase of 0.21% in the week of January 26 to January 30, 2026, ranking 10th among all industries [15] - The report notes that the approval of 177 domestic online games in January 2026 indicates a positive regulatory environment for the gaming industry [33]

Investment Rating - The investment rating for the home appliance industry is "Positive" (maintained) [4] Core Insights - The rise of AI NAS, driven by Clawdbot, is expected to expand the demand for NAS, with Ugreen Technology likely to benefit significantly from this trend [5][14] - TCL Electronics is set to collaborate with Sony to take over Sony's television business, potentially allowing them to surpass Samsung and become the global leader in market share [22][23] - Stone Technology has launched new domestic floor cleaning robots, focusing on dual technology lines to enhance market penetration [25] - XGIMI continues to experience high growth overseas, with its new product Horizon 20 performing well in international markets [28] Summary by Sections AI NAS and Ugreen Technology - Clawdbot's popularity signifies a shift in AI applications towards local AI agents, creating a demand for edge hardware [8] - NAS is positioned as the optimal hardware for local AI agents due to its data centralization, low power consumption, and scalable computing power [11][12][13] - Ugreen Technology, as a leading consumer NAS provider in China, is expected to gain from the increased demand for local data platforms driven by AI agents [14][16] TCL Electronics and Sony Collaboration - TCL Electronics plans to establish a joint venture with Sony to manage Sony's home entertainment business, which could enhance their global market share [22] - This partnership is anticipated to leverage TCL's resources in panel production and Sony's brand strength to penetrate high-end markets [23] Stone Technology's Product Launch - Stone Technology has introduced two new high-end floor cleaning robots, targeting different market segments with innovative features [25] - The G30S Pro series and P20 Ultra are designed to address existing pain points in cleaning efficiency and user experience [25] XGIMI's Overseas Growth - XGIMI's Horizon 20 has shown strong sales performance in international markets, indicating successful product positioning and market strategy [28] - The company is expected to continue its growth trajectory as it challenges established competitors in the high-end projector market [28] Market Performance - The home appliance sector experienced a decline of 2.9% in the week of January 26 to January 30, 2026, underperforming against the Shanghai Composite Index [32][35] - Specific segments such as black appliances saw a significant drop of 7.2%, indicating varying performance across categories [32]

Investment Rating - The investment rating for the precious metals industry is "Positive" (maintained) [5] Core Viewpoints - The report indicates that despite recent fluctuations in gold and silver prices, the long-term logic for precious metals remains intact. The recent price movements are attributed to various factors including the Federal Reserve's decision to maintain interest rates and political developments in the U.S. [4][6] - The report emphasizes that the "Trump 2.0" and "rate cut trade" themes will continue to provide strong momentum for gold prices in the medium term. It suggests that investors should look for phase-specific allocation opportunities [6] - Long-term expectations are that the combination of "rate cut trade" and "Trump 2.0" will catalyze further price increases for gold, supported by central bank purchases and geopolitical factors [6] Price Trends - Over the past two weeks, as of January 30, 2026, London spot gold increased by 8.04% to $4,981.85 per ounce, while the Shanghai gold price rose by 12.51% to ¥1,161.42 per gram. The holding volume for Shanghai gold decreased by 5.88% to 326,700 contracts [11] - London spot silver rose by 13.65% to $103.19 per ounce, and the Shanghai silver price increased by 24.28% to ¥27,941 per kilogram, with Shanghai silver holding volume down by 8.54% to 657,700 contracts [11] - The report notes that palladium prices increased by 3.70% to $1,820 per ounce, while platinum prices slightly decreased by 0.04% to $2,300 per ounce [11] Economic Data and Federal Reserve Tracking - The report highlights the importance of upcoming U.S. economic data releases, including the ADP employment numbers and unemployment rates, which are expected to influence market sentiment and precious metal prices [6] - The Federal Reserve's current stance is viewed as appropriate, with a focus on balancing inflation and employment risks, which may extend the timeline for potential rate cuts [6] Holding and Trading Volume - The report provides insights into the trading volumes, noting a decrease in holding volumes for both gold and silver in the Shanghai market, indicating a potential shift in market sentiment [11] Price Differentials and Futures Basis - The report states that the gold price differential between domestic and international markets has increased, with the current differential at ¥62.04 per gram, up from two weeks prior [61] - The international gold basis (spot-futures) has risen to $74.35 per ounce, indicating a tightening market [63]

证券研究报告 房地产 行业定期报告 hyzqdatemark 2026 年 02 月 01 日 证券分析师 邓力 SAC：S1350525070006 dengli@jzsec.com 陈颖 SAC：S1350525110002 chenying02@huayuanstock.com 唐志玮 tangzhiwei@huayuanstock.com 国务院支持旅居项目建设，关注地产板块配置价值 投资评级： 看好（维持） ——房地产行业周报（26/1/24-26/1/30） | | | 投资要点： 请务必仔细阅读正文之后的评级说明和重要声明 板块行情：本周上证指数下跌 0.4%、深证成指下跌 1.6%、创业板指下跌 0.1%、沪深 300 上 升 0.1%、房地产（申万）下跌 2.2%。个股方面，涨跌幅前五的分别为：大悦城(+17.1%)、 京能置业(+12.5%)、新城控股(+11.4%)、京投发展(+7.7%)、招商蛇口(+7.1%)，涨跌幅后五 的分别为：华联控股(-14.9%)、西藏城投(-13.6%)、城建发展(-12.9%)、华夏幸福(-11.9%)、 万通发展(-11.5%)。 联系人 板块表现： ...

Fixed Income - The report analyzes the new regulatory framework for insurance companies, highlighting five major changes aimed at improving asset-liability management [9][10] - The insurance industry's solvency indicators declined in Q3 2025, attributed to increased equity capital usage and dual pressure on liabilities [11] - Investment returns improved due to rising long-term bond yields and favorable A-share performance, reducing overall industry risk [12] - A selection of insurance subordinated bonds with specific criteria is recommended for investment, including those from major state-owned insurance companies [14] Pharmaceutical Industry - The pharmaceutical index fell by 3.31% recently, with a notable trend of Chinese innovative drugs expanding into international markets [15][17] - Companies like China Biopharmaceutical are enhancing their R&D capabilities through acquisitions and self-developed products, positioning themselves for potential overseas opportunities [18] - A focus on innovative drugs is recommended, with specific companies highlighted for their strong fundamentals and potential for stock price recovery [19] New Consumption - Ruoyu Chen and Wancheng Group are projected to see significant profit growth in 2025, driven by their proprietary brand business and operational efficiency improvements [21][23] - The government is promoting new service consumption growth points, aiming to enhance service supply and consumer experience [25][26] - The snack retail sector is evolving, with companies like Mingming Hen Mang rapidly expanding and innovating to meet consumer demands [24] North Exchange - The North Exchange indices saw over 6% growth in January 2026, indicating a market rebound and highlighting specific sectors for investment opportunities [28][29] - The overall market liquidity remains ample, with a focus on structural investment opportunities in specialized and innovative enterprises [29][30] Media - Alibaba's FY2026Q3 revenue is expected to reach 288.1 billion yuan, with cloud business growth anticipated despite a slowdown in e-commerce [32]

Investment Rating - The investment rating for the non-ferrous metals industry is "Positive" (maintained) [4] Core Views - The report indicates that macroeconomic fluctuations are intensifying, leading to potential price adjustments for copper and aluminum. The copper prices may experience volatility due to a strong dollar and profit-taking by long positions in the market. Meanwhile, aluminum prices are also expected to face similar adjustments due to macroeconomic pressures [3][4]. Summary by Sections 1. Industry Overview - The macroeconomic environment is characterized by the Federal Reserve's decision to maintain interest rates at 3.75% during its January meeting, with Kevin Warsh nominated as the next Fed Chair, viewed as a hawkish choice [9]. - Initial jobless claims in the U.S. exceeded expectations, indicating potential economic challenges [9]. 2. Market Performance - The non-ferrous metals sector outperformed the Shanghai Composite Index, with a weekly increase of 3.37%, while the index itself fell by 0.44% [11]. - The sector ranked fourth among all sectors in terms of performance, with notable movements in gold, copper, and tungsten [11]. 3. Price and Inventory Changes - Copper prices saw an increase of 3.54% in London and 2.31% in Shanghai, while aluminum prices fluctuated with a 4.89% increase in Shanghai but a 1.39% decrease in London [22][36]. - Inventory levels for copper and aluminum showed mixed trends, with copper inventories increasing and aluminum inventories showing both increases and decreases across different markets [22][36]. 4. Specific Metal Insights - **Copper**: The report notes a potential shift from a tight balance to a shortage in the copper supply-demand landscape, driven by insufficient capital expenditure in copper mining and frequent supply disruptions [5]. - **Aluminum**: The aluminum market is expected to face a supply surplus in the short term, but with stable demand growth, a potential shortage may arise later in the year [5]. - **Lithium**: Despite a seasonal downturn, lithium demand remains strong, with a reversal in supply-demand dynamics expected to drive prices upward [5]. - **Cobalt**: The cobalt market is experiencing tight supply conditions, with prices expected to continue rising due to structural constraints [5]. 5. Recommendations - The report suggests monitoring specific companies within the sector, including Zijin Mining, Jiangxi Copper, and Ganfeng Lithium, which are positioned to benefit from the anticipated market dynamics [5].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Viewpoints - The Chinese biopharmaceutical sector is expected to enter a new era of innovative drug exports in 2026, with significant opportunities arising from strategic acquisitions and internal research and development [3][8] - The report emphasizes the importance of selecting strong fundamental innovative drug stocks that have undergone sufficient adjustments, as well as actively monitoring new medical technologies and companies poised for recovery in 2026 [4][41] Summary by Sections Industry Performance - From January 26 to January 30, the pharmaceutical index fell by 3.31%, underperforming the CSI 300 index by 3.39%. Notably, the market has seen a significant adjustment in the innovative drug sector since August 2025, with the lowest holdings in active funds since 2021 [5][21] - The report highlights that 58 stocks rose while 407 stocks fell during the week, with notable gainers including Cap Bio (+26.49%) and Hualan Biological (+12.80%) [5][22] Company Insights - China Biopharmaceutical is enhancing its core competitiveness through strategic acquisitions and self-research, which is expected to lead to more opportunities for international expansion. The acquisition of Hegia in January 2026 and Lixin Pharmaceutical in July 2025 are key moves to strengthen its pipeline in chronic diseases and oncology [8][13] - The report identifies Hegia's siRNA delivery technology as a significant advancement, allowing for long-lasting treatment options in chronic diseases, while Lixin's unique LM-TME platform is expected to enhance the company's capabilities in oncology [9][11][14] Investment Recommendations - The report suggests focusing on innovative drug companies such as Heng Rui Medicine, Xin Li Tai, and China Biopharmaceutical, as well as companies involved in new medical technologies like AI healthcare and brain-computer interfaces [41][43] - It also highlights the potential for recovery in the medical device and pharmaceutical manufacturing sectors in 2026, recommending stocks that are currently undervalued [41][42] Market Trends - The report notes that the Chinese pharmaceutical industry has completed a transition from generic to innovative drugs, with companies like Heng Rui Medicine and China Biopharmaceutical leading the way in innovation [41][42] - The aging population and increasing healthcare demands are expected to drive growth in the sector, supported by a stable increase in medical insurance revenues and the development of a multi-tiered payment system [41][42]

Report Industry Investment Rating - Not provided in the content Core Views of the Report - The new "Insurance Company Asset - Liability Management Measures (Draft for Comment)" has five major changes, aiming to strengthen the supervision of insurance companies' asset - liability management and guide long - term operations [2]. - In 25Q3, the solvency indicators of the insurance industry declined, mainly due to the increase in equity capital occupation and the pressure on both the asset and liability sides [2]. - The rise in long - term bond yields and the good performance of the A - share market in 25Q3 improved the investment returns of the insurance industry and reduced industry risks, but the credit risks of some under - performing insurers need attention [2]. - Large - scale life insurance companies have an advantage in scale premium growth, while small and medium - sized insurers show significant differentiation [2]. - The issuance scale of insurance sub - debt has shrunk [2]. Summary by Relevant Catalogs New "Insurance Company Asset - Liability Management Measures (Draft for Comment)" - **Five major changes**: System integration, organizational framework improvement, clear regulatory indicators, optimized indicator calculation methods, and improved regulatory measures [2][4]. - **Regulatory indicators for property insurance companies**: Precipitation fund coverage ratio to prevent short - term fund long - term investment, income coverage ratio and pressure - scenario liquidity coverage ratio to guide long - term operations [2][5]. - **Regulatory indicators for life insurance companies**: Effective duration gap to prevent asset - liability table fluctuations, comprehensive investment income coverage ratio and net investment income coverage ratio to guide long - term operations [2][5]. 25Q3 Insurance Industry Solvency - **Solvency indicators**: The comprehensive solvency ratio was 186.3% and the core solvency ratio was 134.3%, down 18.2 and 13.5 percentage points respectively from 25Q2, mainly due to the decline of life insurance companies [2]. - **Reasons for the decline**: Increased equity asset allocation, higher risk factors for equity assets under the new rules, and pressure on both the asset and liability sides [2]. 25Q3 Insurance Industry Investment and Profit - **Investment returns**: The rise in long - term bond yields and the good performance of the A - share market improved investment returns, with the total net profit of most insurers with outstanding insurance sub - debt increasing from 92.7 billion yuan in Q2 to 246.9 billion yuan in Q3 [2][24]. - **Profit differentiation**: Among 41 insurers with available data and outstanding insurance sub - debt, property insurance companies' net profit decreased by 3.306 billion yuan in 25Q3, while life insurance companies' net profit increased by 155.65 billion yuan [2]. Scale Premium Growth of Insurance Companies - **Large - scale life insurance companies**: As of 25Q3, China Post Life and New China Life had year - on - year scale premium growth rates of 18.65% and 17.96% respectively, showing relatively high and stable growth [2]. - **Small and medium - sized life insurance companies**: There was significant differentiation, with some companies having high growth rates and others having negative growth [2]. Insurance Sub - debt Issuance - **Issuance scale**: In 2024, 117.5 billion yuan of insurance sub - debt was issued, with 57.3 billion yuan in 24Q3. In 2025, 104.2 billion yuan was issued, a 11.3% year - on - year decrease. As of January 22, 2026, only 5 billion yuan was issued [2]. Investment Recommendations - Screened state - owned and central - owned enterprise insurance company sub - debt with a valuation yield > 2.2%, core solvency ratio > 100%, comprehensive solvency ratio > 150%, and risk comprehensive rating of BBB or above, such as 24 China Property Insurance Capital Supplementary Bond, 25 Great Wall Life Perpetual Bond 01, etc. [3]

Investment Rating - The report suggests a focus on the company, with a recommendation to pay attention to its competitive position in the orthopedic surgical solutions market [4][42]. Core Insights - The company, Aide Technology, specializes in orthopedic consumables and has a projected net profit of 77.75 million yuan for 2025, reflecting a year-on-year increase of 15.82% [4][39]. - The company plans to use the funds raised from its IPO for expanding production capacity, building a research center, and developing a marketing network, which is expected to enhance sales scale and market share [12][14]. - The orthopedic medical device market in China is projected to reach 24.6 billion yuan by 2024, with significant growth in various segments such as spinal implants and trauma devices [42][50]. Company Overview - Aide Technology was established in 2006 and focuses on the research, production, and sales of orthopedic medical devices, including spinal, trauma, and sports medicine products [14][39]. - The company holds 110 patents and has several core products certified by the EU CE authority [14][39]. - The sales model primarily relies on distributors, with the top five customers accounting for 31.87% of total sales in the first half of 2025 [35][36]. Financial Performance - Revenue is projected to grow from 262 million yuan in 2023 to 302 million yuan in 2025, with a compound annual growth rate (CAGR) of 2% from 2022 to 2025 [39]. - The gross margin is expected to decline slightly from 62.45% in 2022 to 58.90% in 2025, while the net profit margin is projected to decrease from 32.70% to 25.85% over the same period [39][41]. Industry Insights - The orthopedic medical device industry is rapidly growing, with the market for orthopedic implants expected to reach 24.6 billion yuan by 2024 [42][50]. - The spinal implant market specifically is projected to grow to 7.2 billion yuan in 2024, despite a temporary decline due to national procurement policies [46][48]. - The trauma implant market is also expected to recover, reaching 3.9 billion yuan in 2024, following a downturn in previous years [52].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The report anticipates that Alibaba's cloud business will accelerate growth in FY26Q3, while e-commerce growth may slow down [5] - Total revenue for FY26Q3 is expected to reach 288.1 billion RMB, representing a year-on-year growth of 3% [5] - Adjusted EBITA margin is projected to be 11%, with adjusted EBITA declining by 43% to 31 billion RMB, primarily due to ongoing investments in the Taobao Flash Sale business [5] Financial Forecasts - For the Chinese e-commerce group, revenue is expected to be 164.3 billion RMB, with an adjusted EBITA margin of 23% [5] - The international digital commerce group is projected to generate revenue of 40.8 billion RMB, with an adjusted EBITA margin of -5% [5] - The cloud intelligence group is expected to achieve revenue of 42.9 billion RMB, with an adjusted EBITA margin of 9% [5][6] Business Segment Analysis - The Chinese e-commerce group is facing growth pressure due to a high base effect and overall industry slowdown, with revenue expected to grow by only 3% [7] - The company aims to become the market leader in the Taobao Flash Sale segment, with significant investments planned to achieve this goal [7] - The international digital commerce group is focusing on key regions to enhance operational efficiency, with revenue expected to grow by 8% [8] Profitability and Valuation - The forecasted net profit for FY2026 is 116.1 billion RMB, with a year-on-year decline of 11% [8] - The projected PE ratios for FY2026, FY2027, and FY2028 are 25, 23, and 17 times, respectively [8] - The report highlights a focus on e-commerce and cloud business segments, with the company maintaining a "Buy" rating due to its strategic initiatives [9]